Trilogy Transcatheter Heart Valve System
JenaValve Technology, Inc. · Decision date Mar 17, 2026
What did the FDA approve?
The FDA approved the Trilogy Transcatheter Heart Valve System from JenaValve Technology, Inc. for treating symptomatic, severe native tricuspid aortic valve regurgitation. The approval excludes cases caused by acute endocarditis, rheumatic heart disease, or acute aortic dissection.
Eligibility requires a Heart Team, including a cardiac surgeon, to judge the patient at high or greater risk for surgical aortic valve replacement. That judgment uses a predicted 30-day surgical mortality of 8% or higher based on the Society of Thoracic Surgeons risk score and other clinical co-morbidities not measured by the STS risk calculator.
FDA approval order statement
The Trilogy Transcatheter Heart Valve System is indicated for the treatment of symptomatic, severe native tricuspid aortic valve regurgitation (not due to acute endocarditis, rheumatic heart disease, or acute aortic dissection) in patients who are judged by a Heart Team, including a cardiac surgeon, to be at high or greater risk for surgical aortic valve replacement (i.e., predicted risk of surgical mortality >=8% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical co-morbidities unmeasured by the STS risk calculator).
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Mar 17, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P250024
- Regulatory pathway
- Premarket approval application
- Applicant
- JenaValve Technology, Inc.
- Product code
- NPT
- Decision code
- APPR
- Decision date
- Mar 17, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Aortic valve, prosthesis, percutaneously delivered.
- Applicant
- JenaValve Technology, Inc.
- Product code
- NPT
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P250024 received
Application receipt date recorded by FDA.
P250024 · FDA decision
APPR
P250024/S006 · Related supplement
Trilogy Transcatheter Heart Valve System
P250024/S005 · Related supplement
Trilogy Transcatheter Heart Valve System
Timeline entries are records held by MedtechLedger for P250024. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250024
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Trilogy Transcatheter Heart Valve SystemP250024/S006 | JenaValve Technology, Inc. | PMA supplement | Oct 7, 2026 | FDA |
Trilogy Transcatheter Heart Valve SystemP250024/S005 | JenaValve Technology, Inc. | PMA supplement | Oct 13, 2026 | FDA |
Explore the linked device profile
Other records with product code NPT
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA supplement | Nov 7, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 29, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Oct 28, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Oct 22, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Sep 23, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
JenaValve Technology, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 4 Cromwell, Irvine, CA, 92618
Sources and methodology
- Original FDA record: P250024
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
